Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1/2 1

Status

Completed 10Recruiting 3Terminated 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Observational 4Interventional 3

Sponsor

Cancer Type

Endocrine 3

Conditions

Breast Neoplasms 1328Neoplasms 998Carcinoma, Non-Small-Cell Lung 865Prostatic Neoplasms 730Colorectal Neoplasms 671Lung Neoplasms 553Leukemia, Myeloid, Acute 475Neoplasm Metastasis 427Pancreatic Neoplasms 426Carcinoma, Hepatocellular 407Ovarian Neoplasms 393Multiple Myeloma 393Stomach Neoplasms 383Recurrence 369Squamous Cell Carcinoma of Head and Neck 327Melanoma 295Uterine Cervical Neoplasms 288Brain Neoplasms 288Triple Negative Breast Neoplasms 273Glioblastoma 263Head and Neck Neoplasms 260Precursor Cell Lymphoblastic Leukemia-Lymphoma 256Endometrial Neoplasms 238Lymphoma 230Esophageal Neoplasms 226Rectal Neoplasms 224Sarcoma 213Carcinoma, Renal Cell 205Colonic Neoplasms 196Lymphoma, Large B-Cell, Diffuse 194

Interventions

fimepinostat 1Deamino Arginine Vasopressin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Interventional × Pituitary ACTH Hypersecretion × Clear all
NCT04569591 2026-04-09

DDAVP for Pituitary Adenoma

National Institutes of Health Clinical Center (CC)

Phase NA Recruiting
22 enrolled
Endocrine

Pituitary Neoplasms, Pituitary ACTH Hypersecretion

NCT05971758 2025-07-04

Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease

University of California, Los Angeles

Phase 2 Recruiting
20 enrolled
Endocrine

Pituitary ACTH Hypersecretion

NCT05804669 2025-04-10

A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome

Crinetics Pharmaceuticals Inc.

Phase 1/2 Recruiting
18 enrolled
Endocrine

ACTH Syndrome, Ectopic, Cushing Syndrome, Pituitary ACTH Hypersecretion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡